Document is current
Any future updates will be listed below
-
Authors
Radyk, Megan D.
Nelson, Barbara S.
Ruckert, Mariana Tannus https://orcid.org/0000-0002-8282-4454
Halbrook, Christopher J.
Shan, Mengrou
Alektiar, Jonathan M. https://orcid.org/0000-0002-3343-0993
Lavoie, Brooke L.
Salvatore, Lucie
Yan, Wei
Perricone, Matthew D.
Buscher, Kathryn
Wood, Alexander
Hong, Hanna S.
Sajjakulnukit, Peter
Zhang, Li
Corfas, Gabriel
Bednar, Filip
Frankel, Timothy L.
Pasca di Magliano, Marina
Colacino, Justin A. https://orcid.org/0000-0002-5882-4569
Shah, Yatrik M. https://orcid.org/0000-0002-2487-4816
Crawford, Howard C. https://orcid.org/0000-0001-9360-3019
Lyssiotis, Costas A. https://orcid.org/0000-0001-9309-6141
- License Information
-
More Information
Article History
Received: 30 October 2024
Accepted: 3 March 2026
First Online: 1 April 2026
Competing interests
: In the past 3 years, C.A.L. has consulted for Astellas Pharmaceuticals, Odyssey Therapeutics, Third Rock Ventures and T-Knife Therapeutics and is an inventor on patents pertaining to Kras-regulated metabolic pathways, redox control pathways in pancreatic cancer and targeting the GOT1–ME1 pathway as a therapeutic approach (US Patent No. 2015126580-A1, 05/07/2015; US Patent No. 20190136238, 05/09/2019; International Patent No. WO2013177426-A2, 04/23/2015). G.C. was the scientific founder of Decibel Therapeutics, had equity interest in the company and received compensation for consulting. The company was not involved in this study. The remaining authors declare no competing interests.
